"Cancer"

According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!

There are many diseases that may recur after treatment, so many head and neck cancer patients are worried about such a situation, and their frequent ruminations may cause a lot of psychological stress to them.

It is estimated that ninety percent of deaths from breast cancer are caused by complications from metastasis, so how to effectively stop breast cancer metastasis has long been a hot topic in cancer research.

Silver fungus contains nitrates, which are converted into nitrites when they enter the body, and nitrites are carcinogenic.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.

Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.

Eye cancer is a very dangerous disease, and as the disease develops, it will affect the patient's body more and more, so it is important for eye cancer patients to receive timely treatment.

For many patients after early lung cancer surgery, it is common for them to worry about recurrence. For this reason, many patients tend to undergo CT examinations more closely to ensure that they have not had a recurrence. However, a recent new study conducted by researchers from Washington University School of Medicine in St. Louis found that even with more frequent CT reviews, post-operative outcomes for lung cancer did not improve...

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.